.png){kind=icon}
.png){kind=icon}
Return
Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye
.png){kind=icon}
PRE
AI
H
A
S
A
S
K
N
A
I
N
P
O
E
S
E
H
C
H
O
G
M
E
B
E
H
D
H
E
T
A
H
H
M
N
M
O
K
I
F
O
A
M
B
Y
N
E
A
D
E
H
H
T
S
E
E
I
H
G
B
L
B
H
C
B
S
O
M
O
I
R
B
F
C
F
U
A
A
M
F
U
A
S
Y
Ş
C
H
O
E
E
H
A
E
N
M
H
H
O
A
F
S
N
S
S
B
C
A
C
Y
R
T
E
M
B
H
R
DOI：10.1007/s12072-026-11139-8.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic metabolic disorder associated with extrahepatic organ damage, including chronic kidney disease (CKD). The Fibrosis-4 (FIB-4) index is a validated non-invasive tool for estimating hepatic fibrosis severity. This study aimed to investigate whether FIB-4-defined hepatic fibrosis is independently associated with reduced estimated glomerular filtration rate (eGFR) in a large, real-world Turkish MASLD cohort. This is a cross-sectional analysis of the prospective, nationwide, multicenter DAHUDER MASLD Study, which enrolled patients from 44 internal medicine outpatient clinics across 31 provinces representing all 12 statistical regions of Türkiye. A total of 10,873 MASLD patients were included. MASLD was defined as ultrasonographic hepatic steatosis in the presence of at least one cardiometabolic risk factor. High FIB-4 was defined as ≥ 1.3 for patients aged < 65 years and ≥ 2.0 for those aged ≥ 65 years, per EASL–EASD–EASO 2024 guidelines. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Age-stratified multivariate linear regression models were constructed to identify independent predictors of eGFR. High FIB-4 was detected in 11.2% of the patients (n = 1219). Patients with high FIB-4 had significantly lower eGFR compared to those with low FIB-4 (85.37 ± 21.08 vs. 94.18 ± 20.17 mL/min/1.73 m2, p < 0.001). FIB-4 score was negatively correlated with eGFR (r = − 0.149, p < 0.001). In age-stratified multivariate analysis adjusted for diabetes mellitus, hypertension, BMI, sex, SGLT2 inhibitor use, and uric acid, FIB-4 score remained an independent predictor of reduced eGFR in both age groups (< 65 years: B = − 2.586, 95% CI [− 3.025, − 2.148], p < 0.001; ≥ 65 years: B = − 1.384, 95% CI [− 2.326, − 0.443], p = 0.004). eGFR decreased progressively across cardiometabolic risk score categories, from approximately 105 mL/min/1.73 m2 (score 1) to approximately 87 mL/min/1.73 m2 (score 5). KDIGO-based staging revealed a higher prevalence of advanced CKD stages in the high FIB-4 group (p < 0.001). Hepatic fibrosis severity, as quantified by the FIB-4 index, is independently associated with impaired kidney function in patients with MASLD beyond established cardiometabolic risk factors. These findings support the role of FIB-4 as a simple, cost-effective tool for integrated cardio-hepato-renal risk stratification. Clinicians should systematically monitor renal function in MASLD patients, particularly those with elevated FIB-4 scores.
Keywords:
MASLD
FIB-4 index
Chronic kidney disease
Glomerular filtration rate
Hepatic fibrosis
Metabolic syndrome
Cardiometabolic risk
Türkiye
Journal
IF:
6.1
Papers:
2.1K
Citations:
5.9K
Organization
Cited Papers